Hospital Procurement Strategies in Orthobiologics Market Evolve

Hospital procurement strategies for orthobiologics are evolving beyond simply seeking the lowest cost, with healthcare providers now prioritizing factors such as supply chain resilience and clinical outcomes. This shift aims to mitigate risks associated with product shortages and ensure continuity of care.

The orthobiologics market is projected to grow from USD 6.0 billion in 2026 to USD 8.6 billion by 2036, at a CAGR of 3.7%. Within product segments, bone graft substitutes are expected to dominate, holding 49.8% of the market share in 2026. This growth is driven by their increasing use in spinal fusion, trauma repair, and reconstructive surgeries.

Historically, hospitals often favored single-supplier contracts for simplified inventory management and potential volume discounts. However, recent global supply chain disruptions have prompted many institutions to develop multi-supplier strategies. This approach enhances operational resilience and ensures consistent availability of critical orthobiologic products.

Procurement negotiations now place significant emphasis not only on pricing but also on clinical performance, regulatory compliance, and reliable delivery schedules. Suppliers offering comprehensive orthopedic portfolios and long-term service support are increasingly favored for multi-year contracts. Physician preference and robust clinical data also remain central to purchasing decisions.

Large integrated delivery networks and health systems are frequently negotiating enterprise-wide contracts. Companies that can provide a broad range of orthopedic products and manufacturing capabilities under a single agreement may benefit from these consolidated purchasing models. The market remains competitive as hospitals balance financial efficiency with access to advanced regenerative technologies.